Ferring Wins In Combo Exclusivity Case; FDA Lacks 'Legitimate Reason' To Reject
Court finds FDA erred in not giving the fixed-dose combo product Prepopik five years of market exclusivity since it had awarded the exclusivity to similarly situated single-entity drug products.
You may also be interested in...
Otsuka claimed Alkermes' Aristada is 'legally equivalent' to Abilify but DC Circuit deferred to FDA's finding that the two have different active moieties and thus Abilify's three-year exclusivity does not apply to Aristada.
Citizen petition seeks five-year NCE exclusivity for Pfizer’s estrogen/bazedoxifene combo after district court tells FDA its inconsistent position is unreasonable.
Final guidance on the tropical disease priority review voucher program says FDA will adhere to priority review goals, which allow agency to complete some outside the stated time frame.